DBVT News and Press, DBV Technologies S.A. From 10/04/19

DBV Technologies ( DBVT +2.8% ) says the Food and Drug Administration has accepted the Biologics License Application for its Viaskin peanut immunotherapy for the treatment of peanut-allergic children aged 4-11; shares are halted. More news on: DBV Technologies S.A., Healthcare stocks n...

Montrouge, France, October 4, 2019 DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut for the Treatment of Peanut Allergy If approved, Viaskin Peanut would be the first and only epicutaneous immunotherapy indicated for this potentially life-threatening condition in...

We haven't covered Aimmune Therapeutics, Inc. ( AIMT ) as much as we should, barring an article comparing Aimmune and its distant competitor DBV Technologies ( DBVT ), where we said that AIMT is probably the better investment. Late last year, after DBVT withdrew its US marketing application ...

Montrouge, France, August 7, 2019 DBV Technologies Submits Biologics License Application to U.S. Food and Drug Administration for Viaskin Peanut for the Treatment of Peanut Allergy DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopha...

Montrouge, France, August 1, 2019 DBV Technologies Reports First Half 2019 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported first half 2019 financial results. The inte...

AMF REGULATED INFORMATION Montrouge, France, July 18, 2019 Amendment to the DBV Technologies Liquidity Contract with NATIXIS ODDO BHF and Half-Year Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical...

Aimmune Therapeutics ( AIMT -6.5% ) is down on below-average volume on the heels of a cautionary report on peanut allergy treatments by the non-profit Institute for Clinical and Economic Review (ICER). More news on: Aimmune Therapeutics, Inc., DBV Technologies S.A., Healthcare stocks...

Gainers:  Oasmia Pharmaceutical OASM  +76% . Xenetic Biosciences (NASDAQ: XBIO ) +41% . Tyme Technologies TYME  +22% . Gol Linhas Aereas Inteligentes S.A. GOL  +19% . BIOLASE (NASDAQ: BIOL ) +16% . OHR Pharmaceutical (NASDAQ: OHRP ) +15% . Cool Holdings (NASDAQ: AWSM...

Oasmia Pharmaceutical AB (NASDAQ: OASM ) +51% . More news on: Oasmia Pharmaceutical AB (publ), Tyme Technologies, Inc., DBV Technologies S.A., Stocks on the move, Read more ...

Montrouge, France, June 26, 2019 DBV Technologies Announces Appointment of Pharis Mohideen, M.D., as Chief Medical Officer   Dr. Mohideen brings extensive experience in clinical drug development Dr. Hugh Sampson to continue serving as Chief Scientific Officer DBV Technol...